A deal has been reached between the BC government and the maker of a drug that slows the progression of ALS symptoms.
The Health Ministry says supplying patients with ALS, also known as Lou Gehrig's disease, with the drug Radicava would cost about 120,000 dollars a year for each patient.
The ministry says it expects as many as 183 patients will get coverage in the first year.
The deal was worked out under the pan-Canadian Pharmaceutical Alliance and the ministry says it meet B.C.'s cost mandate.